Document is current
Any future updates will be listed below
-
Authors
Shadman, Mazyar https://orcid.org/0000-0002-3365-6562
Harper, Jennifer S. https://orcid.org/0009-0007-7431-0983
Bokun, Alex
Xu, Chang
Lin, Pei
Graf, Gloria
Lu, Xiaoxiao
-
Funding
Funding for this research was provided by:
Johnson and Johnson
- License Information
-
More Information
Article History
Received: 28 May 2025
Revised: 23 October 2025
Accepted: 11 November 2025
First Online: 5 December 2025
Competing interests
: MS has received consultancy fees and/or research funding from AbbVie, Genentech, AstraZeneca, Genmab, Janssen, BeiGene, Bristol Myers Squibb, Morphosys/Incyte, Kite Pharma, Eli Lilly, Fate Therapeutics, Nurix, Merck, Mustang Bio, Vincerx, and Koi Biotherapeutics. Employment: Bristol Myers Squibb (spouse). JSH, AB, CX, PL, GG, and XL are employees of Johnson & Johnson and may hold company stock. JSH holds a patent assigned to Johnson & Johnson.
